-
64 drugs getting temporary price cuts
27 Jun 2024 17:29 GMT
… 2025, as part of further Medicare Prescription Drug Inflation Rebate Program actions … $2,000.
The 64 drugs available to Medicare Part B enrollees at …
Fosaprepitant
Fragmin
Fyarro
Gemcitabine
Imlygic
Ixempra
Kepivance
Kimmtrak
Kinevac
Krystexxa
Kymriah …
-
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
14 May 2024 20:01 GMT
… stage pharmaceutical company dedicated to developing personalized cancer treatments, … a follow-on trial with FDA regulatory intent. … clinical outcome from drug treatment in cancer patients dozens … significant unmet medical needs in cancer treatment. For more …
-
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer
28 Mar 2024 20:39 GMT
… (OS) with ixabepilone (Ixempra) plus bevacizumab (Avastin) … Maryland Medical System in Baltimore.
The trial was … bevacizumab in chemotherapy-resistant ovarian cancer.2
The trial’s … based on prior bevacizumab treatment.
Regarding statistical analyses, …
-
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27 Mar 2024 12:30 GMT
… other clinical trials for dovitinib and IXEMPRA®. An additional … with Jiangsu Hengrui Pharmaceuticals, involving an upfront … clinical outcome from drug treatment in cancer patients in 37 … addressing significant unmet medical needs in cancer treatment. For more …
-
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
05 Dec 2023 12:30 GMT
… inhibitor therapy and chemotherapy, showed significant … pharmaceutical company developing novel oncology therapeutics together with drug … M.D., Chief Medical Officer of Allarity. … trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer …
-
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
24 Jul 2023 10:00 GMT
… pharmaceutical company developing novel oncology therapeutics together with drug … , oncology, and medical device markets. Prior … where he mentors doctoral candidates. Bob has … trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer …
-
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
05 Jul 2023 13:45 GMT
… stage pharmaceutical company developing novel oncology therapeutics together with drug- … chemotherapies in the metastatic setting. Allarity recently amended the clinical trial … trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, …
-
Allarity Therapeutics Shares Rise 87% After Positive Early Ixempra Data in Europe
05 Jul 2023 15:06 GMT
… 2 clinical trial evaluating the efficacy of Ixempra in metastatic breast cancer patients …
-
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023
27 Apr 2023 20:10 GMT
… trial for IXEMPRA®, the clinical-stage pharma company's metastatic breast cancer treatment … developed by Bristol Myers Squibb, IXEMPRA is a small … Using drug-specific DRP® companion diagnostics, doctors will be … in over 47 cancer trials, the DRP® platform …
-
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
28 Mar 2023 10:00 GMT
… pharmaceutical company developing novel oncology therapeutics together with drug … “Similarly, our trial protocol amendments reflect … to Smerud Medical Research International AS … trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer …
About
© 1995-2025